Integrating best practices in AI, genomics, cell culture, and laboratory techniques together contribute to protein expression success.

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Phase 3 Ovarian Cancer Trial to Initiate in March 2025 Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial ...

Scientists at VCU Massey Comprehensive Cancer Center have identified an innovative combination of treatment strategies that work collaboratively to effectively kill acute myeloid leukemia (AML) cells, ...

Beyond manufacturing capacity, sponsors seek expertise in specialized drug formulations, regulatory affairs, and service ...